# Blood Coagulants Market

> Middle East & Africa Blood Coagulants Market Research Report Information, By Types (Coagulation Factor, others), Indication (Haemophilia, Surgery, other Bleeding Disorders) -Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.47%
- **2024:** $ 11.39 Billion
- **2025:** $ 12.25 Billion
- **2035:** $ 22.79 Billion
- **Key Players:** Baxter International (US), Boehringer Ingelheim (DE), Johnson & Johnson (US), Roche (CH), CSL Behring (AU), Amgen (US), Grifols (ES), Octapharma (CH), Sobi (SE)

**Report ID:** MRFR/Pharma/2027-CR · **Pages:** 53 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** January 30, 2026

**URL:** https://www.marketresearchfuture.com/reports/blood-coagulants-market-2743

---

## Market Summary

## **Middle East & Africa Blood Coagulants Market Overview**

The Middle East & Africa Blood Coagulants Market is expected to grow USD 2.77 Billion at a CAGR 6.70% during the forcast period 2023 to 2030. Coagulation is the process, by which blood changes from a liquid to a gel, forming a blood clot. In general terms, coagulation is a process in which the blood forms clots to block and then heal a lesion/wound/cut and stop the bleeding.

The Middle East & Africa blood coagulants market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. 

In the Middle East and Sub-Saharan Africa, bleeding disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.

As per the study published in Blood Coagulation Fibrinolysis journal, 2016, it is reported that in the Yaoundé Hemophilia Treatment Center (HTC) of Cameroon multiple cases of hemophilia and von willebrand disease (VWD) have been registered According to the 2014 Annual Global Survey of World Federation of Hemophilia (WFH), in 2014 the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von willebrand disease, and 1,123 with other bleeding disorders.

It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years A  research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia in Saudi Arabia and most dominant in male patients: 1 : 5000 to 10,000. Whereas, prevalence rate of hemophilia B: 1: 34,500 male patients

The Middle East & Africa blood coagulants market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding,

[healthcare insurance](../../../reports/health-insurance-market-8227)

coverage, and awareness programs for bleeding disorders. On the other hand, there are certain factors that also hinder the growth of this market such as lack of R&D capabilities in the regions, presence of counterfeit drugs, and lack of awareness in most of the parts of developing and underdeveloped countries in the region.

**Figure- MEA blood coagulants market, by Country 2016 (%)**

Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis 

**Intended Audience:**

**Research Methodology:**
****

Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis 

## **Middle East & Africa Blood Coagulants Market Segmentation  **  

The Middle East & Africa blood coagulants market is segmented on the basis of types, indications, and by country.

On the basis of types, the Middle East & Africa blood coagulants market is segmented into coagulation factor and others. Coagulation factor is further segmented into recombinant coagulation factor, plasma coagulation factor, and others.

On the basis of indication, the Middle East & Africa blood coagulants market is segmented into haemophilia, surgery, other

[bleeding disorders](../../../reports/bleeding-disorders-treatment-market-6592)

, and others. Haemophilia is further divided into haemophilia A and haemophilia B.

On the basis of country, the Middle East & Africa blood coagulants market is segmented into KSA, UAE, Qatar, Oman, Kuwait, Egypt, and Rest of Middle East & Africa. 

## **Middle East & Africa Blood Coagulants Market Regional Analysis**

The Middle East & Africa blood coagulants market is segmented on the basis of countries into Saudi Arabia (KSA), United Arab Emirates (UAE), Qatar, Oman, Kuwait, Egypt, and rest of Middle East & Africa. Saudi Arabia account for the largest market share of the Middle East & Africa blood coagulants market by countries in 2016. The large share is majorly attributed to increasing prevalence of the haemophilia disease in this country, high usage of the expensive recombinant coagulation factors for the treatment, and high disposable income of the population, and better healthcare facilities in this country. 

**Key Findings:**

## **Key Players for Middle East & Africa Blood Coagulants Market**

Some of the major players in Middle East & Africa blood coagulants market are: 

## Market Drivers

### Rising Geriatric Population

The aging population in the Middle East and Africa is contributing to the demand for blood coagulants, as older adults are more susceptible to bleeding disorders and related complications. This demographic shift is influencing healthcare priorities and resource allocation within the Global Middle East & Africa Blood Coagulants Market Industry. As the geriatric population continues to grow, healthcare providers are increasingly focusing on preventive measures and effective treatment options. This trend is likely to bolster market growth, aligning with the overall increase in healthcare expenditure and the anticipated market value of 1250 USD Million in 2024.

### Advancements in Biotechnology

Technological innovations in biotechnology are reshaping the Global Middle East & Africa Blood Coagulants Market Industry. New recombinant factor therapies and bioengineered products are being developed, offering enhanced efficacy and safety profiles compared to traditional treatments. These advancements are likely to attract investment and research efforts, fostering a competitive landscape. As a result, the market is anticipated to grow at a CAGR of 7.43% from 2025 to 2035. The introduction of novel therapies not only improves patient outcomes but also addresses the unmet needs of various bleeding disorders, thereby expanding the overall market.

### Market Trends and Projections

The Global Middle East & Africa Blood Coagulants Market Industry is witnessing dynamic trends that reflect the evolving landscape of healthcare. Projections indicate a market value of 1250 USD Million in 2024, with an anticipated growth trajectory leading to 2750 USD Million by 2035. The compound annual growth rate (CAGR) of 7.43% from 2025 to 2035 underscores the increasing demand for innovative blood coagulants. This growth is driven by factors such as technological advancements, demographic shifts, and enhanced healthcare policies, which collectively shape the future of the market.

### Growing Awareness and Education

There is a notable increase in awareness and education regarding bleeding disorders and the importance of blood coagulants in the Global Middle East & Africa Blood Coagulants Market Industry. Educational campaigns and outreach programs are being implemented to inform patients and healthcare professionals about available treatments. This heightened awareness is likely to lead to earlier diagnosis and treatment, ultimately improving patient outcomes. As more individuals seek effective therapies, the market is expected to experience substantial growth, with projections indicating a market value of 2750 USD Million by 2035.

### Government Initiatives and Funding

Government initiatives aimed at improving healthcare infrastructure and access to treatment are pivotal for the Global Middle East & Africa Blood Coagulants Market Industry. Various countries are implementing policies to enhance the availability of blood coagulants, particularly in underserved regions. Increased funding for healthcare programs and partnerships with pharmaceutical companies are facilitating the development and distribution of essential therapies. This proactive approach is expected to drive market growth, with projections indicating a market value of 1250 USD Million in 2024 and a potential rise to 2750 USD Million by 2035, reflecting the commitment to improving health outcomes.

### Increasing Prevalence of Hemophilia

The rising incidence of hemophilia and other bleeding disorders in the Global Middle East & Africa Blood Coagulants Market Industry is a critical driver. Hemophilia affects approximately 1 in 5,000 male births, leading to a growing demand for effective coagulant therapies. This trend is particularly evident in regions with limited access to treatment, where patients rely heavily on blood coagulants for managing their conditions. As awareness and diagnosis improve, the market is expected to expand significantly, contributing to the projected market value of 1250 USD Million in 2024 and potentially reaching 2750 USD Million by 2035.

## Future Outlook

The Blood Coagulants Market is projected to grow at a 6.47% CAGR from 2025 to 2035, driven by technological advancements, increasing surgical procedures, and rising awareness of coagulation disorders.

**New opportunities:**

- Development of personalized coagulant therapies for specific patient profiles. Expansion of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900) services for remote monitoring of coagulation levels. Investment in AI-driven analytics for predictive modeling in coagulation management.

By 2035, the Blood Coagulants Market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Application: Surgical Procedures (Largest) vs. Cardiovascular Disorders (Fastest-Growing)

The application segment of the Blood Coagulants Market displays a diverse distribution, with Surgical Procedures commanding the largest share. This dominance is attributed to the increasing volume of surgeries performed globally, as well as advancements in surgical techniques and technologies that enhance patient outcomes. Other significant contributors to this market include Trauma Care and Chronic Conditions, but their shares are comparatively smaller. The share of Orthopedic Procedures and Cardiovascular Disorders, while notable, reflects a niche focus within the broader category.
Market trends show a robust growth trajectory for the Blood Coagulants Market, particularly in the Cardiovascular Disorders segment, which is currently the fastest-growing application area. Factors driving this growth include an increase in cardiovascular surgeries, rising awareness of blood clotting disorders, and improved diagnostic techniques that facilitate timely interventions. Additionally, the aging population and the prevalence of lifestyle-related health issues continue to fuel demand for blood coagulants, indicating a promising outlook for this segment.

Surgical Procedures (Dominant) vs. Trauma Care (Emerging)

Surgical Procedures remain the dominant application in the Blood Coagulants Market due to the high frequency of surgeries and the critical need for effective bleeding control during these interventions. The consistent rise in elective surgeries alongside emergency procedures has heightened the reliance on blood coagulants, ensuring their vital role in surgical settings. On the other hand, Trauma Care is emerging as a crucial application, driven by the increasing incidence of accidents and injuries that necessitate immediate blood clotting solutions. As healthcare systems emphasize trauma readiness and improve emergency response capabilities, the demand for effective coagulant products in this area is expected to surge. This dynamic reflects a growing awareness among healthcare providers of the importance of swift intervention in trauma situations.

### By End Use: Hospitals (Largest) vs. Home Healthcare (Fastest-Growing)

In the Blood Coagulants Market, hospitals account for the largest share of end use, driven by their extensive patient base and the necessity for rapid and reliable coagulation treatments in emergency scenarios. Ambulatory surgical centers and specialty clinics also contribute significantly, but their shares are smaller compared to hospitals and home healthcare settings. The demand in hospitals reflects their central role in managing critical medical conditions requiring blood coagulation treatments, reinforcing their dominance in this segment.

Hospitals (Dominant) vs. Home Healthcare (Emerging)

Hospitals serve as the cornerstone of the Blood Coagulants Market, utilizing advanced technologies and protocols to ensure effective coagulation management for patients during surgeries and trauma cases. Their established infrastructure supports a wide range of coagulant products, including both traditional and novel agents. On the other hand, home healthcare is rapidly emerging as a significant segment due to the increasing preference for at-home treatments and the growing aging population. Innovations in portable coagulant testing and administration enable patients to manage their conditions effectively at home, reflecting the shifting dynamics of blood coagulation management, where convenience and patient autonomy are becoming vital.

### By Type: Vitamin K Antagonists (Largest) vs. Direct Oral Anticoagulants (Fastest-Growing)

In the Blood Coagulants Market, the segment distribution reveals that Vitamin K Antagonists currently hold the largest market share, attributable to their longstanding use in managing coagulation disorders. This segment remains favored by healthcare professionals for their proven efficacy and established treatment protocols, cementing their role in patient management. On the other hand, Direct Oral Anticoagulants are rapidly gaining traction, appealing particularly to younger patients due to their ease of use and more predictable pharmacodynamics. As healthcare systems evolve, the adoption of these newer agents is reshaping overall market dynamics.

Vitamin K Antagonists (Dominant) vs. Direct Oral Anticoagulants (Emerging)

Vitamin K Antagonists have long been the standard in anticoagulation therapy, typically used in conditions like atrial fibrillation and venous thromboembolism. Their dominance stems from extensive clinical experience and a wide-ranging physician familiarity. However, Direct Oral Anticoagulants are redefining the anticoagulation landscape by offering advantages such as fixed dosing and fewer dietary restrictions. As clinical guidelines begin to adapt, these emerging agents are expected to grow significantly, supported by ongoing clinical research, more favorable safety and efficacy profiles, and increased patient education, which may eventually position them as the new standard of care.

### By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

In the Blood Coagulants Market, the route of administration plays a crucial role in product efficacy and patient compliance. Among the primary routes—oral, intravenous, and subcutaneous—intravenous administration holds the largest market share. This is primarily attributable to its rapid onset of action and suitability for patients in acute settings, such as surgical procedures or trauma cases. In contrast, oral administration, while favored for its convenience, tends to have limitations regarding absorption and efficacy for certain coagulant therapies.

The growth trends within this segment showcase a significant shift towards subcutaneous administration, which has emerged as the fastest-growing route. Innovations in drug formulations and delivery devices have enhanced patient convenience and compliance, driving increased adoption among healthcare providers. Factors such as patient preference for home administration and technological advancements in injectable formulations are propelling this growth, indicating a dynamic evolution in the delivery methods for blood coagulants.

Intravenous (Dominant) vs. Subcutaneous (Emerging)

Intravenous administration of blood coagulants is recognized as the dominant method due to its immediate effect in critical clinical situations. This route ensures that the drug enters the systemic circulation rapidly, making it particularly effective for situations requiring quick intervention. It is often the preferred choice in hospitals and emergency medical care. On the other hand, subcutaneous administration is gaining traction as an emerging alternative, particularly for long-term anticoagulation therapy. Its ease of use and suitability for self-administration enable patients to manage their treatment from home, thereby improving adherence and quality of life. Both methods are crucial, catering to the varying needs of patient demographics and clinical scenarios.

### By Patient Demographics: Adult (Largest) vs. Geriatric (Fastest-Growing)

The Blood Coagulants Market is significantly influenced by patient demographics, with the adult cohort commanding the largest share. Adults typically have higher incidences of conditions requiring coagulation therapies, such as surgeries and chronic diseases. In contrast, pediatric patients represent a smaller market segment, but they are vital in terms of specialized formulations and age-appropriate dosing, contributing to the overall market dynamics. Growth trends indicate that the geriatric population is becoming the fastest-growing segment due to the increasing prevalence of age-related health disorders and the rising number of surgeries among older adults. As life expectancy increases, a greater emphasis on managing coagulopathies and other related conditions in geriatrics is fueling market expansion.

Pediatric (Emerging) vs. Geriatric (Dominant)

In the Blood Coagulants Market, the adult segment stands out as the dominant force, driven by a higher prevalence of coagulation disorders and a greater need for coagulation management. Adults often have diverse health issues that necessitate the use of blood-coagulating treatments. Conversely, the geriatric segment is emerging rapidly as a significant market player, prompted by an aging global population and their specific medical needs. Pediatric use of blood coagulants is also gaining attention, although it remains a niche market, focusing on tailored therapies for younger patients with congenital coagulopathies. The growth of geriatric applications is reshaping market strategies, with a distinct focus on usability and effectiveness for older patients.

## Regional Market Share Analysis

### North America : Market Leader in Coagulants

North America is poised to maintain its leadership in the blood coagulants market, holding a significant market share of 5.5 in 2024. The region's growth is driven by increasing incidences of bleeding disorders, advancements in medical technology, and supportive regulatory frameworks. The demand for innovative therapies and personalized medicine is also on the rise, further propelling market expansion. The competitive landscape is characterized by the presence of major players such as Baxter International, Johnson & Johnson, and Amgen. The U.S. is the leading country, supported by robust healthcare infrastructure and high healthcare expenditure. The market is also witnessing strategic collaborations and mergers among key players to enhance product offerings and market reach.

### Europe : Emerging Market Dynamics

Europe is experiencing a notable increase in the blood coagulants market, with a market size of 3.5 in 2024. The growth is fueled by rising awareness of bleeding disorders, an aging population, and advancements in treatment options. Regulatory bodies are actively promoting research and development, which is expected to further enhance market dynamics. The region's focus on improving healthcare access and quality is also a significant driver. Leading countries in this region include Germany, France, and the UK, where major players like Boehringer Ingelheim and Roche are prominent. The competitive landscape is evolving, with an emphasis on innovative therapies and partnerships. The European Medicines Agency continues to support the market with favorable regulations, ensuring a conducive environment for growth.

### Asia-Pacific : Rapidly Growing Market Potential

The Asia-Pacific region is witnessing rapid growth in the blood coagulants market, with a market size of 2.5 in 2024. This growth is driven by increasing healthcare investments, rising awareness of bleeding disorders, and a growing patient population. Governments are implementing policies to enhance healthcare infrastructure, which is expected to further boost market demand. The region's diverse healthcare needs present significant opportunities for market players. Countries like China, India, and Japan are leading the market, with key players such as CSL Behring and Grifols expanding their presence. The competitive landscape is marked by a mix of local and international companies striving to innovate and capture market share. The region's focus on improving healthcare access is likely to drive further growth in the coming years.

### Middle East and Africa : Emerging Market Opportunities

The Middle East and Africa region is gradually emerging in the blood coagulants market, with a market size of 0.89 in 2024. The growth is attributed to increasing healthcare investments, rising awareness of bleeding disorders, and improving healthcare infrastructure. Governments are focusing on enhancing healthcare access, which is expected to drive demand for blood coagulants in the region. Leading countries include South Africa and the UAE, where there is a growing presence of international players like Octapharma and Sobi. The competitive landscape is evolving, with local companies also entering the market to meet the rising demand. Regulatory bodies are working towards establishing guidelines to ensure the safety and efficacy of blood coagulants, fostering a conducive environment for growth.

## Competitive Benchmarking

The Blood Coagulants Market is characterized by a dynamic competitive landscape, driven by increasing demand for advanced therapeutic solutions and a growing prevalence of bleeding disorders. Key players such as Baxter International (US), Boehringer Ingelheim (DE), and CSL Behring (AU) are strategically positioned to leverage innovation and expand their market presence. Baxter International (US) focuses on enhancing its product portfolio through research and development, while Boehringer Ingelheim (DE) emphasizes strategic partnerships to bolster its therapeutic offerings. CSL Behring (AU) is actively pursuing regional expansion, particularly in emerging markets, which collectively shapes a competitive environment that is increasingly focused on innovation and collaboration.The Blood Coagulants Market exhibits a moderately fragmented structure, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is essential in maintaining competitive pricing. The collective influence of major players fosters a competitive atmosphere where innovation and operational efficiency are paramount, allowing companies to differentiate themselves in a crowded marketplace.
In November Baxter International (US) announced the launch of a new line of recombinant factor products aimed at treating hemophilia. This strategic move is significant as it not only enhances Baxter's product offerings but also positions the company to capture a larger share of the hemophilia treatment market, which is experiencing robust growth. The introduction of these products is expected to meet the rising demand for effective and safe treatment options, thereby reinforcing Baxter's competitive edge.
In October Boehringer Ingelheim (DE) entered into a collaboration with a leading biotechnology firm to develop next-generation blood coagulants. This partnership is indicative of Boehringer's commitment to innovation and reflects a broader trend in the industry towards collaborative research efforts. By leveraging external expertise, Boehringer aims to accelerate the development of novel therapies, which could potentially transform treatment paradigms in the coagulant space.
In September CSL Behring (AU) expanded its manufacturing capabilities in Asia, a strategic decision aimed at enhancing supply chain reliability and meeting the growing demand in the region. This expansion not only positions CSL Behring to better serve its customers but also underscores the importance of localized production in maintaining competitive advantage. The move is likely to improve operational efficiencies and reduce lead times, which are critical in the fast-paced healthcare environment.
As of December the Blood Coagulants Market is witnessing trends such as digitalization, sustainability, and the integration of AI technologies. These trends are reshaping competitive dynamics, with companies increasingly forming strategic alliances to enhance their capabilities. The shift from price-based competition to a focus on innovation, technology, and supply chain reliability is evident. Moving forward, competitive differentiation will likely hinge on the ability to innovate and adapt to changing market demands, positioning companies to thrive in an evolving landscape.

## Report Scope

| MARKET SIZE 2024 | 11.39(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 12.25(USD Billion) |
| MARKET SIZE 2035 | 22.79(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.47% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Baxter International (US), Boehringer Ingelheim (DE), Johnson & Johnson (US), Roche (CH), CSL Behring (AU), Amgen (US), Grifols (ES), Octapharma (CH), Sobi (SE) |
| Segments Covered | Application, End Use, Type, Route of Administration, Patient Demographics |
| Key Market Opportunities | Advancements in personalized medicine enhance treatment options in the Blood Coagulants Market. |
| Key Market Dynamics | Rising demand for innovative blood coagulants drives competitive forces and regulatory adaptations in the healthcare sector. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Blood Coagulants Market by 2035?**
A: The Blood Coagulants Market is projected to reach a valuation of 22.79 USD Million by 2035.

**Q: What was the market valuation of the Blood Coagulants Market in 2024?**
A: In 2024, the Blood Coagulants Market was valued at 11.39 USD Million.

**Q: What is the expected CAGR for the Blood Coagulants Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Blood Coagulants Market during the forecast period 2025 - 2035 is 6.47%.

**Q: Which companies are considered key players in the Blood Coagulants Market?**
A: Key players in the Blood Coagulants Market include Baxter International Inc., Boehringer Ingelheim, Johnson & Johnson, and Roche Holding AG.

**Q: What are the primary applications of blood coagulants in the market?**
A: The primary applications of blood coagulants include Surgical Procedures, Trauma Care, Chronic Conditions, Cardiovascular Disorders, and Orthopedic Procedures.

**Q: How do hospitals contribute to the Blood Coagulants Market?**
A: Hospitals accounted for a market segment valuation of 4.55 USD Million in 2024, indicating their significant role in the Blood Coagulants Market.

**Q: What types of blood coagulants are available in the market?**
A: Available types of blood coagulants include Vitamin K Antagonists, Direct Oral Anticoagulants, Thrombin Inhibitors, and Factor Xa Inhibitors.

**Q: What routes of administration are utilized for blood coagulants?**
A: Blood coagulants are administered through Oral, Intravenous, and Subcutaneous routes, with Intravenous being valued at 4.56 USD Million in 2024.

**Q: How does the patient demographic segment affect the Blood Coagulants Market?**
A: The patient demographic segment includes Pediatric, Adult, and Geriatric categories, with Adults representing a market valuation of 6.0 USD Million in 2024.

**Q: What is the significance of ambulatory surgical centers in the Blood Coagulants Market?**
A: Ambulatory Surgical Centers contributed a market valuation of 2.27 USD Million in 2024, highlighting their relevance in the Blood Coagulants Market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/blood-coagulants-market-2743*